Amgen To Present Lumakras Combination Data From Phase 1b Stu

THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy

Related Keywords

, Virtual International Conference On Molecular , Drugging Difficult Target , International Conference , Molecular Targets , Cancer Therapeutics , Amgen , Present , Lumakras , Combination , Data , Rom , Hase , Study , Ras , 12c , Mutated , Cancers ,